Cryoport, Inc. (NASDAQ:CYRX) Receives $11.50 Average Target Price from Analysts

Shares of Cryoport, Inc. (NASDAQ:CYRX) have been given an average rating of “Moderate Buy” by the six analysts that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $11.50.

A number of research analysts have commented on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Cryoport in a report on Wednesday, March 5th. Guggenheim started coverage on Cryoport in a report on Thursday, December 19th. They issued a “buy” rating and a $11.00 price objective on the stock.

Cryoport Stock Up 1.2 %

CYRX stock opened at $6.49 on Thursday. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $323.92 million, a PE ratio of -1.92 and a beta of 1.67. Cryoport has a 1-year low of $4.58 and a 1-year high of $20.11. The business’s 50 day simple moving average is $7.03 and its 200 day simple moving average is $7.46.

Cryoport (NASDAQ:CYRX) last posted its earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.09). The business had revenue of $59.53 million for the quarter, compared to analyst estimates of $58.71 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. During the same period in the previous year, the firm posted ($0.29) earnings per share. As a group, research analysts anticipate that Cryoport will post -0.99 EPS for the current year.

Institutional Trading of Cryoport

A number of institutional investors have recently modified their holdings of CYRX. PharVision Advisers LLC bought a new stake in shares of Cryoport during the 4th quarter worth $259,000. Squarepoint Ops LLC lifted its position in shares of Cryoport by 208.4% during the 4th quarter. Squarepoint Ops LLC now owns 36,499 shares of the company’s stock worth $284,000 after buying an additional 24,665 shares during the last quarter. State of Wyoming lifted its position in shares of Cryoport by 170.2% during the 4th quarter. State of Wyoming now owns 32,426 shares of the company’s stock worth $252,000 after buying an additional 20,427 shares during the last quarter. Sherbrooke Park Advisers LLC bought a new stake in shares of Cryoport during the 4th quarter worth $116,000. Finally, Silvercrest Asset Management Group LLC raised its position in Cryoport by 77.0% in the fourth quarter. Silvercrest Asset Management Group LLC now owns 742,914 shares of the company’s stock valued at $5,780,000 after purchasing an additional 323,216 shares during the last quarter. 92.90% of the stock is currently owned by institutional investors.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.